Preventive effect of a heparinoid-containing product on the application site reaction of the rotigotine transdermal patch in Parkinson’s disease: A pilot randomized clinical trial (the SkinHeRo study)

INTRODUCTION: The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD) but is sometimes discontinued because of application site reactions (ASRs). We aimed to investigate the effect of a heparinoid-containing product (HCP) for preventing ASRs due to the RTP...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, Jinsoo, Takahashi, Maiko, Sakata, Mayumi, Yasui, Masaaki, Yorozu, Shoko, Ito, Hidefumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379504/
https://www.ncbi.nlm.nih.gov/pubmed/34458718
http://dx.doi.org/10.1016/j.prdoa.2021.100105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379504/
https://www.ncbi.nlm.nih.gov/pubmed/34458718
http://dx.doi.org/10.1016/j.prdoa.2021.100105

Ejemplares similares